Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXOZYMES INC.EXOZ · Entity 1147 | Chief Scientific Officer | August 19, 2026 | August 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXOZYMES INC.
Report date August 19, 2026 · Filed August 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 762,837 |
Reported balance
After 2026-08-19 transaction · row 1
1 source rowRow 1 · 2026-08-19 · Exercise / conversion · Acquired 32,964 · Balance 762,837 F1: The RSU convert on a one-for-one basis. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 46,140 |
Reported balance
After 2026-08-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-19 · Exercise / conversion · Disposed 32,964 · Balance 46,140 F1: The RSU convert on a one-for-one basis. F2: On March 28, 2022, and May 1, 2023, the reporting person was granted an aggregate of 79,104 RSUs, vesting periodically. The first vesting was August 19, 2026, in the amount of 32,964 shares of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The RSU convert on a one-for-one basis.
F2: On March 28, 2022, and May 1, 2023, the reporting person was granted an aggregate of 79,104 RSUs, vesting periodically. The first vesting was August 19, 2026, in the amount of 32,964 shares of common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2026 Filed Aug 25, 2026 22:57 UTC | EXOZYMES INC. EXOZ · Entity 1147 | Exercise / conversionRestricted Stock Unit · Derivative | 32,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-040116 · ownership.xml · derivative · entry 2 Korman Tyler Paz · CIK 0002032745 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,140 Underlying: Common Stock · 32,964 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The RSU convert on a one-for-one basis. F2 · derivative.exercise_date: On March 28, 2022, and May 1, 2023, the reporting person was granted an aggregate of 79,104 RSUs, vesting periodically. The first vesting was August 19, 2026, in the amount of 32,964 shares of common stock. F2 · derivative.expiration_date: On March 28, 2022, and May 1, 2023, the reporting person was granted an aggregate of 79,104 RSUs, vesting periodically. The first vesting was August 19, 2026, in the amount of 32,964 shares of common stock. Read SEC document |
| August 19, 2026 Filed Aug 25, 2026 22:57 UTC | EXOZYMES INC. EXOZ · Entity 1147 | Exercise / conversionCommon Stock | 32,964 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-040116 · ownership.xml · nonDerivative · entry 1 Korman Tyler Paz · CIK 0002032745 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 762,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The RSU convert on a one-for-one basis. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 20:30 UTC | EXOZYMES INC. EXOZ · Entity 1147 | SaleCOMMON STOCK | 750 | $10.53 | $7,893.75 |
DisclosureSEC source: 0001493152-26-016166 · ownership.xml · nonDerivative · entry 2 Korman Tyler Paz · CIK 0002032745 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 729,123 Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 20:30 UTC | EXOZYMES INC. EXOZ · Entity 1147 | SaleCOMMON STOCK | 750 | $10.04 | $7,530.45 |
DisclosureSEC source: 0001493152-26-016166 · ownership.xml · nonDerivative · entry 1 Korman Tyler Paz · CIK 0002032745 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 729,873 Read SEC document |
| April 01, 2026 Filed Apr 8, 2026 10:14 UTC | EXOZYMES INC. EXOZ · Entity 1147 | GrantCOMMON STOCK | 5,332 | $8.44 | $45,002.08 |
DisclosureSEC source: 0001493152-26-015619 · ownership.xml · nonDerivative · entry 1 Korman Tyler Paz · CIK 0002032745 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 730,623 Read SEC document |
| June 16, 2025 Filed Jun 17, 2025 21:22 UTC | EXOZYMES INC. EXOZ · Entity 1147 | GrantCommon Stock | 2,990 | $12.54 | $37,494.60 |
DisclosureSEC source: 0001641172-25-015460 · ownership.xml · nonDerivative · entry 1 Korman Tyler Paz · CIK 0002032745 · Vice President, Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 725,291 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.